HomeCompareEIGRQ vs VIG

EIGRQ vs VIG: Dividend Comparison 2026

EIGRQ yields 23.53% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGRQ wins by $58.2K in total portfolio value
10 years
EIGRQ
EIGRQ
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full EIGRQ calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — EIGRQ vs VIG

📍 EIGRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGRQ + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGRQ pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGRQ
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, EIGRQ beats the other by $8,065.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGRQ + VIG for your $10,000?

EIGRQ: 50%VIG: 50%
100% VIG50/50100% EIGRQ
Portfolio after 10yr
$61.4K
Annual income
$4,919.46/yr
Blended yield
8.02%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGRQ buys
0
VIG buys
9
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$VIG▲ Buy$1,001 - $15,0002024-05-16
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002023-12-28
Ro Khanna🏢 House$VIG▼ Sell$15,001 - $50,0002023-05-04
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
Joe Courtney🏢 House$VIG▼ Sell$1,001 - $15,0002020-10-09
K. Michael Conaway🏢 House$VIG▼ Sell$50,001 - $100,0002020-09-08
K. Michael Conaway🏢 House$VIG▲ Buy$15,001 - $50,0002020-05-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQVIG
Forward yield23.53%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$90.5K$32.3K
Annual income after 10y$9,663.72$175.21
Total dividends collected$55.7K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EIGRQ vs VIG ($10,000, DRIP)

YearEIGRQ PortfolioEIGRQ Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$13,053$2,352.94$11,301$160.59+$1.8KEIGRQ
2$16,837$2,870.36$12,752$162.91+$4.1KEIGRQ
3$21,476$3,460.26$14,370$165.02+$7.1KEIGRQ
4$27,104$4,124.87$16,176$166.93+$10.9KEIGRQ
5$33,867$4,865.30$18,188$168.67+$15.7KEIGRQ
6$41,919$5,681.51$20,432$170.25+$21.5KEIGRQ
7$51,425$6,572.30$22,933$171.68+$28.5KEIGRQ
8$62,561$7,535.33$25,720$172.98+$36.8KEIGRQ
9$75,507$8,567.24$28,827$174.15+$46.7KEIGRQ
10$90,456$9,663.72$32,288$175.21+$58.2KEIGRQ

EIGRQ vs VIG: Complete Analysis 2026

EIGRQStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Full EIGRQ Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this EIGRQ vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGRQ vs SCHDEIGRQ vs JEPIEIGRQ vs OEIGRQ vs KOEIGRQ vs MAINEIGRQ vs DGROEIGRQ vs NOBLEIGRQ vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.